IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.636
AS - Asia 5.422
EU - Europa 2.724
SA - Sud America 1.829
AF - Africa 122
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 20.747
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.476
SG - Singapore 3.221
BR - Brasile 1.608
CN - Cina 1.165
FI - Finlandia 743
IE - Irlanda 509
DE - Germania 302
FR - Francia 282
VN - Vietnam 279
IN - India 208
NL - Olanda 186
GB - Regno Unito 184
HK - Hong Kong 157
IT - Italia 144
SE - Svezia 91
AR - Argentina 86
BD - Bangladesh 71
CA - Canada 59
MX - Messico 57
BE - Belgio 51
PL - Polonia 50
TR - Turchia 50
EC - Ecuador 44
RU - Federazione Russa 42
ZA - Sudafrica 40
IQ - Iraq 35
ID - Indonesia 34
JP - Giappone 34
ES - Italia 31
UA - Ucraina 26
CO - Colombia 21
UZ - Uzbekistan 21
AE - Emirati Arabi Uniti 18
PK - Pakistan 18
MA - Marocco 17
NG - Nigeria 17
PY - Paraguay 16
SA - Arabia Saudita 16
CZ - Repubblica Ceca 14
LT - Lituania 14
DO - Repubblica Dominicana 13
KE - Kenya 13
PE - Perù 13
UY - Uruguay 13
VE - Venezuela 13
CL - Cile 11
EG - Egitto 11
IL - Israele 11
TN - Tunisia 11
JO - Giordania 10
PA - Panama 10
KZ - Kazakistan 9
AT - Austria 7
AU - Australia 6
AZ - Azerbaigian 6
KR - Corea 6
CH - Svizzera 5
JM - Giamaica 5
LB - Libano 5
LV - Lettonia 5
NI - Nicaragua 5
NP - Nepal 5
PS - Palestinian Territory 5
RO - Romania 5
BG - Bulgaria 4
DK - Danimarca 4
DZ - Algeria 4
GR - Grecia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
MY - Malesia 4
TW - Taiwan 4
AL - Albania 3
AM - Armenia 3
BO - Bolivia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BW - Botswana 2
ET - Etiopia 2
GT - Guatemala 2
IR - Iran 2
KI - Kiribati 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RS - Serbia 2
TH - Thailandia 2
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
Totale 20.732
Salva come PNG Salva come JPEG
Città #
Chandler 2.264
The Dalles 983
Singapore 840
Ashburn 809
Helsinki 736
Shanghai 681
New York 588
Dublin 507
Princeton 461
Lawrence 460
Boardman 444
Dallas 390
Paris 269
Los Angeles 248
Amsterdam 169
Beijing 163
Hong Kong 151
Pune 141
São Paulo 134
London 111
Ho Chi Minh City 101
Santa Clara 80
Seattle 70
Rio de Janeiro 62
Hanoi 61
Brussels 51
Munich 49
Phoenix 48
Brooklyn 46
Warsaw 40
Belo Horizonte 39
Wilmington 37
Boston 34
Frankfurt am Main 34
Curitiba 33
Milan 33
Council Bluffs 32
Tokyo 31
Assago 30
Stockholm 29
Brasília 28
San Francisco 26
Johannesburg 25
Mexico City 25
Chicago 24
Porto Alegre 24
Chennai 23
Berlin 22
Columbus 21
Atlanta 19
Moscow 19
Falkenstein 18
Montreal 18
Guarulhos 17
Tashkent 17
Benin City 16
Campinas 16
Denver 16
Dhaka 16
Guangzhou 16
Guayaquil 16
Haiphong 16
Istanbul 16
San Mateo 14
Biên Hòa 13
Ankara 12
Baghdad 12
Borås 12
Clifton 12
Montevideo 12
Ribeirão Preto 12
Jakarta 11
Manaus 11
Salvador 11
Amman 10
Da Nang 10
Hanover 10
Osasco 10
Petrópolis 10
Sorocaba 10
São Gonçalo 10
Washington 10
Asunción 9
Blumenau 9
Brno 9
Charlotte 9
Fortaleza 9
Goiânia 9
Hangzhou 9
Nairobi 9
New Delhi 9
Poplar 9
Quito 9
Reston 9
Sumaré 9
São Vicente 9
Vila Velha 9
Zhengzhou 9
Ann Arbor 8
Betim 8
Totale 12.315
Salva come PNG Salva come JPEG
Nome #
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 124
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 93
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 87
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 85
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 80
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 79
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 77
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 77
Mesothelioma. From research to clinical practice 74
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 74
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics 73
A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging 73
How Medicines are Born. The Imperfect Science of Drugs 71
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 70
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 70
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 70
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 70
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 69
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 69
A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia 68
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 67
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 67
Are we close to the clinical development of novel drugs targeting telomeres and telomerase? 66
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 65
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 64
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 63
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 63
A novel taxane active against an orthotopically growing human glioma xenograft 63
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 63
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 63
A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers 63
Mechanisms of resistance to alkylating agents 62
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 61
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 61
Sequence-specific DNA alkylation of novel tallimustine derivatives 59
A FILTER INCUBATION METHOD FOR THE DETERMINATION OF POTENTIALLY CROSSLINKABLE SITES IN DNA IN MAMMALIAN-CELLS 59
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 59
"The Art of Successful Publication" ECCO 13 workshop report 58
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 58
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 57
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 57
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 57
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue 57
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 56
Genetic Instability Influences Drug Response in Cancer Cells 56
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 56
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 56
SAFETY PROFILE AND TOLERABILITY OF 'TRABECTEDIN AND INDOLE-3-CARBINOL COMBINATION IN REFRACTORY ADVANCED BREAST CANCER. PRELIMINARY RESULTS OF PHASE 1 CLINICAL STUDY 56
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 55
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 55
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 55
Modulation of gene transcription by natural products - A viable anticancer strategy 55
Dalla biologia alle terapie mirate 55
Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles 55
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 55
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 55
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma 55
New drugs from the sea 55
The potential impact of marine compounds in the era of targeting therapies 54
Unique features of the mode of action of ET-743 54
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 54
AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER 54
Vinca alkaloids, taxanes and podophyllotoxins 54
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 54
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour 54
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 53
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer 53
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 53
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 53
Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles 53
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 53
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 53
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 53
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 53
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism 53
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters 52
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 52
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 52
Binding of imatinib by alpha(1)-acid glycoprotein 52
L-asparagine-depletion: Another opinion - Response 52
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 52
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 52
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy 52
Pharmacological study on PEG-Asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 52
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 52
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels 52
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study 52
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer 52
Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer 52
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 51
Idarubicin and melphalan as myeloablative regimen after sequential high dose chemotherapy for lymphomas: Preliminary results of a phase I-II study with pharmaco-kinetical guided peripheral blood progenitor cell reinfusion 51
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 51
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 51
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study 51
Trabectedin therapy for sarcomas 51
Drug development (including phase I trials) 51
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin 51
HMGA1 is a new biomarker of liposarcoma progression 51
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells 51
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 50
Totale 5.991
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202163 0 0 0 0 0 22 9 7 13 5 0 7
2021/2022244 2 4 0 7 1 0 0 7 19 5 67 132
2022/20236.459 1.028 151 587 747 428 615 5 690 1.151 575 412 70
2023/20243.814 333 311 940 283 106 679 113 195 39 176 366 273
2024/20254.849 121 16 21 98 128 615 255 271 1.022 1.228 579 495
2025/20265.351 2.014 895 618 1.257 390 177 0 0 0 0 0 0
Totale 20.782